The medication works by mimicking the natural hormone GLP-1, which regulates appetite, slows gastric emptying, and enhances feelings of satiety
Contrave is a non-stimulant medication that targets appetite and cravings through different brain pathways
The Ct method was used to determine the relative expression of the gene using Hprt1 as a housekeeping gene
Feeding the Hedgehog: A new meaning for JNK signalling in liver regeneration
Daily dosing may cause receptor desensitization, where oxytocin receptors downregulate in response to constant stimulation, reducing the peptide effectiveness over time
A spokesperson for Eli Lilly, which produces Zepbound and Mounjaro, told The Independent that Zepbound and Mounjaro autoinjectors and Zepbound vials are approved for single-use onlydose-splitting or microdosing is not contemplated by the FDA-label and may pose patient safety risks. Novo Nordisk, which produces Ozempic and Wegovy, told The Independent the company "[does] not condone the misuse of our products." The company noted it is concerned about non-FDA approved knock-off versions of semaglutide and sources spreading misinformation about GLP-1s to the public. The FDA warns that using unapproved versions of GLP-1 drugs can be risky for patients. This story was updated on September 4, 2025 to include responses from Eli Lilly and Novo Nordisk Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
